Medicare proposes expanding coverage for anti-obesity meds
The Centers for Medicare & Medicaid Services (CMS) recently proposed a significant policy shift that could transform access to anti-obesity medications. This reinterpretation of Medicare’s statutory exclusion for weight-loss medications would allow coverage for anti-obesity medications under Medicare Part D, extending treatment options to millions of beneficiaries with obesity. The proposal marks a critical step in addressing obesity as a chronic condition rather than solely a lifestyle issue.
What does the CMS proposal include?
The CMS proposal reinterprets the statutory exclusion of medications used for weight loss, allowing these drugs to be covered by Medicare Part D when prescribed to treat obesity. Previously, anti-obesity medications were only covered for other FDA-approved indications, such as managing type 2 diabetes or cardiovascular disease. The new rule seeks to expand Medicare Part D benefits, making these medications accessible to beneficiaries solely for obesity treatment.
Who would benefit from the proposed rule?
If adopted, the CMS proposal would expand access to anti-obesity medications for an estimated 3.4 million Medicare Part D enrollees. These individuals have obesity but do not qualify for anti-obesity medications coverage under the current restrictions. In addition, the Medicaid program would be impacted, with around 4 million adult enrollees potentially gaining access to these treatments. This expanded coverage would significantly improve treatment availability for underserved populations, particularly those with limited financial means.
Obesity in the Medicare and Medicaid populations
Obesity is a pervasive issue among Medicare and Medicaid beneficiaries, with significant health consequences. This chronic condition increases the risk of numerous diseases, including diabetes, heart disease, and certain cancers. Ensuring affordable access to anti-obesity medications is a critical component in managing the broader public health crisis linked to obesity.
Financial implications of the CMS proposal
Expanding coverage for anti-obesity medications comes with considerable costs. CMS estimates that the proposal would cost the Medicare program $24.8 billion over a 10-year period. Similarly, Medicaid spending is projected to rise by $14.8 billion over the same timeframe, with $11 billion funded federally and $3.8 billion borne by state governments. While the upfront costs are substantial, the long-term savings associated with improved health outcomes and reduced complications from obesity-related diseases could offset these expenses.
Out-of-pocket costs for patients
For Medicare Part D enrollees, the financial burden of anti-obesity medications has remained relatively low. In 2023, the average out-of-pocket cost for a one-month supply of these medications was $60, with most patients paying $15 or less. Enrollees in the low-income subsidy program had even lower costs, averaging just $3 per month.
If the CMS proposal is implemented, many beneficiaries could continue accessing these medications at an affordable price.
Why the change matters: Addressing obesity in public health
Obesity is not just a cosmetic concern — it is a chronic disease that significantly impacts physical and mental health. The expanded use of anti-obesity medications offers a promising approach to managing obesity and preventing related conditions like diabetes and cardiovascular disease. By removing barriers to access, CMS aims to help millions of Americans achieve better health outcomes.
Challenges in implementing the proposed rule
One of the main challenges lies in the rising cost of anti-obesity medications. Since 2017, manufacturers have steadily increased the list prices of these drugs, making them more expensive in the U.S. compared to other countries. Balancing expanded access with the financial strain on the health care system will be critical as the proposal moves forward.
Manufacturer pricing trends
The steady rise in U.S. list prices for anti-obesity medications has raised concerns among policymakers and health care providers. Even after accounting for rebates and discounts, prices in the U.S. remain significantly higher than those in comparable countries. This trend could pose challenges for maintaining the affordability of these treatments under Medicare and Medicaid programs.
What does this mean for patients and providers?
The CMS proposal holds the potential to revolutionize the treatment landscape for obesity. By increasing access to innovative medications, the rule could empower millions of patients to take control of their health. However, health care providers and policymakers must navigate challenges related to cost and implementation to ensure equitable access for all beneficiaries.
FAQs
What are anti-obesity medications?
Anti-obesity medications are prescription drugs approved by the FDA to assist in weight management for individuals with obesity.
Why is the CMS proposal significant?
The proposal aims to expand access to anti-obesity medications under Medicare Part D and Medicaid, allowing millions of beneficiaries with obesity to receive necessary treatment.
How will the proposal impact Medicaid enrollees?
If implemented, the proposal would require states covering prescribed drugs to include anti-obesity medications for obesity treatment, potentially benefiting 4 million adult Medicaid enrollees.
What are the projected costs of the proposal?
CMS estimates that expanding coverage will cost Medicare $24.8 billion and Medicaid $14.8 billion over a 10-year period.
Will out-of-pocket costs increase for patients?
Out-of-pocket costs for Medicare Part D enrollees have been relatively low, with most patients paying $15 or less per month. This trend may continue if the proposal is implemented.
If you’re interested in a weight-loss program and want to schedule a free, 10-minute consultation or an appointment with our obesity medicine board-certified doctor, book one below.
